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Abstract
Purpose This review evaluates the application of bone
morphogenetic proteins (BMPs) in delayed bone repair,
aiming at a broad audience from clinicians to scientists.
Next to an overview of the role of the different BMPs, their
antagonists and their current applications, special attention
is focused on new scientific developments improving the
effects of BMP-based therapy for bone repair.
Methods Publication searches in PubMed and Embase
revealed 850 relevant articles on the criteria ‘BMP’ AND
‘bone repair’ (as of May 2011). The abstracts were carefully
reviewed and papers were selected according to the content.
Results The resulting publications showed that BMP-2 and
BMP-7 are clearly the most extensively evaluated BMPs, in
general with positive results on bone healing, comparable
to the use of unspecific preparations such as autologous
bone grafts or platelet-rich plasma.
Conclusions Although the efficacy of BMPs as stimulators
of bone repair has been demonstrated in model systems and
clinical studies, the use of BMPs to enhance fracture
healing in the clinical setting is still controversial. Issues
such as when, where and how much of which BMP is the
most effective and profitable to use still have to be
elucidated. But optimisation of the BMP products used in
combination with cheaper production methods will inevita-
bly stimulate the clinical use of BMPs for bone fracture
healing in the near future.
Abbreviations
ALP Alkaline phosphatase
BMP Bone morphogenetic protein
BAMBI BMP and activin membrane-bound inhibitor
BMP-RI BMP receptor type I
BMP-RII BMP receptor type II
CDMP Cartilage-derived morphogenetic protein
CIZ Cas-interacting zinc finger protein
CRIM1 Cysteine-rich motor neuron 1
GDF Growth and differentiation factor
HIF-1α Hypoxia-inducible factor 1α
PRP Platelet-rich plasma
PTH Parathyroid hormone
rh Recombinant human
Smurf Smad ubiquitin regulatory factor
Smad Combination of Sma and Mad
TGF-β Transforming growth factor-β
Tsg Twisted gastrulation
Wnt Combination of Wg (wingless) and Int
Introduction
The overall incidence of long bone fractures in the Western
world is estimated to be between 300 and 400 individuals
per 100,000 per year [1, 2]. The majority of trauma-induced
fractures in adults will heal within nine months [3]. For
progressive union of a fracture, the factors combined in the
so-called diamond concept need to be present: an adequate
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matrix and mechanical stability. Apparently 5–30% of the
patients lack one of these factors, because they will develop
complications during the healing process, leading to
delayed union or even non-union of the fracture [4]. These
complications may induce prolonged hospitalisation and
secondary interventions with concomitant inconveniences
and costs. Especially for those patients, but eventually for
all patients with fractures, treatments that positively
influence bone healing and subsequently shorten the time
necessary for bone union are of great interest.
Healing of fractures and time to union can be improved
by biophysical stimulation or by administration of biolog-
ical substances, such as autologous bone grafts or platelet-
rich plasma (PRP). The optimal administration dose and the
identity of the active substances in these preparations are
largely unknown. Recent studies into the mechanism of
fracture repair have resulted in the identification of more
specific compounds for intervention. Examples are the
parathyroid hormone (PTH), hypoxia-inducible factor 1α
(HIF-1α), modulators of the Wnt signalling pathway and
the bone morphogenetic proteins (BMPs) [5]. The admin-
istration of defined compounds instead of heterogeneous
mixtures of proteins may result in better treatment options
and could also offer financial advantages. Promising
candidates are the BMPs, which were originally identified
as the active components in bone extracts capable of
inducing de novo bone formation at ectopic sites [6, 7].
This review will focus on the application of recombinant
human BMPs (rhBMPs) in bone repair.
BMPs
Eventhough earlier observations had been made, Urist
published in 1965 the conclusive observations on the
induction of cartilage and bone by demineralised segments
of bone [6]. The osteoinductive activity was found to be
induced by a family of proteins present in bone, which were
named BMPs [8].
BMPs are a subfamily of the transforming growth factor-
β (TGF-β) superfamily, also comprising activins and
inhibins. Thus far, around 20 different proteins have been
named BMP in humans, but not all members are truly
osteogenic (Table 1). The bone-inducing BMPs can be
divided into several subgroups, according to homology of
their amino acid sequences [9, 10]. BMP-2 and BMP-4
comprise one subgroup; the second group consists of BMP-
5, BMP-6, BMP-7 and BMP-8, while BMP-9 and BMP-10
form the third osteogenic group [9, 11]. The other members
of the BMP family do not posses osteogenic properties.
BMP-1 is actually a metalloprotease and not a member of
the superfamily [12], whereas BMP-3 and BMP-13 func-
tion as BMP antagonists/inhibitors rather than as BMPs
[13, 14].
In bone, BMPs are produced by osteoprogenitor cells,
osteoblasts, chondrocytes and platelets [15, 16]. After their
release, the extracellular matrix functions as a temporary
storage for BMPs. The regulatory effects of BMPs depend
upon the target cell type, its differentiation stage, the local
concentration of BMPs, as well as the interactions with
other secreted proteins [4]. BMPs induce a sequential
cascade of events leading to chondrogenesis, osteogenesis,
angiogenesis and controlled synthesis of extracellular
matrix [10] (see Fig. 1).
The BMPs exert their effects through binding as dimers to
type I and type II serine/threonine kinase receptors, forming
an oligomeric complex (Fig. 2). The type II receptors are
constitutively active and phosphorylated and consequently
activate the type I receptors upon oligomerisation. Subse-
quently, the activated type I receptors phosphorylate intra-
cellular effector proteins, the receptor-regulated Smads (R-
Smads), Smad1, Smad5 and Smad8. Upon activation, the
Smads associate with the Co-Smad, Smad4, and translocate
into the nucleus, where they associate with other transcrip-
tion factors and bind promoters of target genes to control
their expression [10, 17–20]( F i g .1).
BMP antagonists and modulators
The activity of BMPs is locally regulated by a number of
antagonists. High expression of BMP antagonists will
negatively influence fracture healing. These antagonists can
be subdivided into molecules that act extracellularly or
intracellularly. Extracellular antagonists such as noggin,
chordin, twisted gastrulation (Tsg), gremlin, follistatin and
BMPER are cystine knot-containing proteins forming com-
plexes with BMPs, thereby preventing them to bind their
receptors [18, 19, 21–24]. Another secreted antagonist is
BMP-3, which induces activation of a TGF-β/activin-like
pathway and as a consequence inhibits signalling by
osteogenic BMPs and bone formation [18, 21, 25]. Inhibition
of BMPs can also occur at the cell membrane. CRIM1, a
transmembrane protein, with cysteine-rich repeats similar to
chordin, regulates the rate of processing and delivery of
BMPs to the cell surface [26]. The pseudo-receptor BAMBI
(BMP and activin membrane-bound inhibitor) is a trans-
membrane protein of which the extracellular domain shares
high sequence similarity with type I receptors, but which
lacks the intracellular kinase domain and is thought to inhibit
BMP signalling by interfering with receptor complex
formation [27]. Endoglin (CD105) is a transmembrane co-
receptor involved in the regulation of a number of members
of the TGF-β superfamily, including TGF-β and BMPs.
Down-regulation of endoglin results in decreased signalling
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activity [28, 29]. Intracellular antagonists such as Smad6,
Smad7 and Smad8b and Smurf1 and Smurf2 intervene with
the activation of R-Smads and/or facilitate their proteasomal
degradation (Fig. 2). Furthermore, apart from its C-terminal
phosphorylation by BMP type I receptors, Smad1 can be
phosphorylated by the Erk, P38 and JNK MAP kinases and
subsequently by GSK-3, which results in cytoplasmic
retention and increased proteasomal degradation of Smad1
[30, 31].
In conclusion, the mere presence of BMPs is no
guarantee of efficient bone healing. Although the presence
of BMPs is essential for a number of processes during bone
healing, BMP-mediated bone formation strongly depends
on the local presence of various BMP activity regulating
inhibitors and stimulators.
Treatment with BMPs
Clinical use of BMPs
Based on various animal studies and preclinical trials,
several clinical studies have been performed to demonstrate
the efficacy of BMPs in accelerating bone regeneration and
fracture healing [32–35]. The osteogenic potency of the
BMPs requires a local and controlled delivery. Moreover,
for clinical use of BMPs, their short half-life time should be
taken into account. Several delivery systems have been
developed to overcome this limitation [4, 36–38].
For clinical use rhBMP-2 (dibotermin alfa), with the
product names InductOs® (UK) and InFUSE (US), is
supplied within a bovine collagen sponge carrier, allowing
slow release over time. This combination has been
thoroughly investigated and was approved by the US Food
and Drug Administration (FDA) in 2004 [39]. Govender et
al. evaluated the effects of rhBMP-2 treatment in 450
patients with open tibial fracture in a prospective setup [32].
Inflammatory
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BMP-6
BMP-7
BMP-8
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Fig. 1 Schematic overview of BMP expression during different stages
of fracture healing [74, 75]. The indicated days are dependent on the
bone and fracture type
Subfamily BMP Synonyms Involved in Refs.
1 BMP-2 BMP-2A Bone and cartilage formation [7, 76]
BMP-4 BMP-2B Teeth and bone formation [76–78]
2 BMP-5 Cartilage development [79]
BMP-6 Vgr-1 Joints, liver [80, 81]
BMP-7 OP-1 Renal development, kidney [82, 83]
BMP-8 OP-2 Bone and cartilage formation [84]
BMP-8B
3 BMP-9 GDF-2 CNS, liver, angiogenesis [78, 85–87]
BMP-10 Morphogenesis of the heart [78, 88]
Others BMP-1 Metalloprotease, cartilage development [12]
BMP-3 Osteogenin BMP inhibitor, bone formation [13]
BMP-3B GDF-10 [20]
BMP-13 GDF-6, CDMP-2 BMP inhibitor, tendons [14]
BMP-11 GDF-11 CNS [78]
BMP-12 GDF-7, CDMP-3 Tendons, cartilage [89]
BMP-14 Cartilage [78, 90]
BMP-15 GDF-9 Oocyte development [91]
BMP-16 ? [92]
Table 1 Overview of BMP
characteristics
GDF growth differentiation fac-
tor, CDMP cartilage-derived
morphogenetic protein
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significantly higher union rate, reduced time to union,
improved wound healing, reduced infection rate and fewer
secondary invasive interventions in the group treated with
rhBMP-2.
The other clinically used BMP , rhBMP-7, with the brand
names Osigraft® (UK) and OP-1 Putty (US), is supplied in
1 g bovine collagen carrier in granular form [40]. In small
but randomised trials, the positive effect of rhBMP-7 on
repair of scaphoid non-unions and fibular defects was
demonstrated [41, 42]. Administration of rhBMP-7 showed
better formation of bone and bridging of the segmental
defects compared to controls. Giannoudis and Tzioupis
evaluated the type of indications and the efficacy for
treatment with rhBMP-7 [34]. A variety of clinical
conditions, such as persistent fracture non-unions, augmen-
tation of periprosthetic fracture treatment and osteotomies,
enhancement of fracture healing following acetabular
reconstruction, distraction osteogenesis, free fibular graft
and arthrodesis of joints, were treated with rhBMP-7. Of
653 cases, the overall success rate was 82% (535 cases)
[34]. Ristiniemi et al. treated 20 patients with distal tibial
fractures that had been stabilised with external fixation with
rhBMP-7 in bovine collagen [43]. Healing of the fracture
was compared with that of 20 matched patients who
received the same treatment only without BMP-7. In the
patients treated with rhBMP-7, significantly more fractures
had healed and time to union was shorter. They concluded
that BMP-7 enhanced the union of distal tibial fracture.
The potency of rhBMP-2 and rhBMP-7 has recently been
compared, in vitro and in vivo [44]. In vitro, both agents
increased the alkaline phosphatase (ALP) production, which
indicated osteogenic differentiation, but the production of
ALP was markedly higher in the rhBMP-2 group than in the
rhBMP-7 group. However, in vivo rhBMP-7 produced
significantly larger ossicles, with significantly more bone
and mineral content. Other in vivo studies showed that
rhBMP-2 could be more potent than rhBMP-7 [23]. These
contradictory results could be the effect of the different
working mechanisms and of the different time frames of the
single BMPs during the process (see Fig. 1) and therefore also
depend on the scaffold in which the BMPs are administrated
[10]. These problems could be circumvented by using more
sophisticated scaffolds, which could even allow the use of
both BMPs in an optimised time frame, with early release of
BMP-2 followed by BMP-7 in a later stage [37].
Platelets contain considerable amounts of BMPs and the
treatment of fractures with PRP is at least in part based on
BMPs [15]. Calori et al. showed, however, that the
application of rhBMP-7 as a bone-stimulating agent is
superior compared to that of PRP with regard to their
clinical and radiological efficacy [33].
Fig. 2 Regulation of the BMP
signalling pathway during bone
formation. 1 BMP binds to BMP
receptor type II (BMP-RII). 2
BMP/BMP-RII complexes with
BMP receptor type I (BMP-RI),
which is then phosphorylated. 3
BMP-RI phosphorylates the
regulatory Smad1, Smad5 and
Smad9, after which a complex is
formed with Smad4. The com-
plex is transported to the nucle-
us and the regulation of target
genes occurs, leading to bone
formation. Further regulation of
the signalling pathway takes
place at various levels. 4 Extra-
cellular BMP inhibitors, e.g.
chordin, noggin, Tsg, gremlin,
follistatin and BMPER. 5 Re-
ceptor antagonists, e.g. BMP-3,
BMP-13. 6 Membrane pseudo-
receptors, e.g. BAMBI, CRIM1,
and co-receptors, e.g. endoglin.
7 Intracellular inhibitors, e.g.
Smad6, Smad7, Smad8b,
Smurf1, Smurf2
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demonstrated the powerful osteoinductive properties of
single recombinant human BMPs, the results of clinical
trials with rhBMP-2 and rhBMP-7 are less impressive. This
was also concluded in a recent Cochrane review, in which
similar times for fracture healing between controls groups
and groups treated with BMP-2 or BMP-7 were demon-
strated [45]. Several possible explanations have been
suggested, such as rapid tissue clearance and lack of
responding cells at time of administration [46]. Some of
the (endogenous) factors possibly contributing to the
limited efficacy of BMP administration will be discussed
in the “Blocking antagonists” section.
Adverse effects of BMPs
Several side effects have been suggested for the use of
rhBMPs in fracture healing. Especially with regard to the
supra-physiological doses, ectopic bone formation and stim-
ulationofcancercellsarebeingstudied.RecombinantBMP-2
h a sr e c e n t l yb e e ns h o w nn o tt ob ea s s o c i a t e dw i t hp a n c r e a t i c
cancer in a study with more than 90,000 patients [47]. The
most frequently described adverse effect is the development
of antibodies against the administrated rhBMPs or against
the bovine collagen carrier [32, 38]. This immunogenic
reaction was found to be positively correlated with higher
doses of BMP and collagen. No correlation between the
immune response to bovine collagen and treatment failure
was demonstrated, and no clinical manifestations of an
immune response or allergies to bovine collagen were found.
Side effects of BMP-2 such as ectopic bone formation in
fracture treatment and critical soft tissue swelling for cervical
spine fusions have also been observed. However, these were
associated with the use of very high BMP doses in animal
studies, varied among species, and ultimately remodelling to
the normal bone contour occurred. Nonetheless, BMPs
remain a potent treatment option to enhance fracture healing
with low risk of adverse events if correctly used. After
administration of rhBMPs, biological negative feedback
loops are activated resulting in the production of BMP
antagonists and culminating in diminished rhBMP activity,
probably influencing therapeutic efficacy. The historical
approach of administrating larger amounts of BMPs in an
effort to enhance the efficacy might result in the opposite
effect. Recent studies using sophisticated biomaterials as
BMP carriers show better results with lower doses,
corresponding more with physiological concentrations [48].
Cost-effectiveness of rhBMPs
Next to the side effects, the use and costs of rhBMPs are
also under debate. BMPs are delicate to handle, expensive
to manufacture and supra-physiological doses are used,
resulting in high costs. Nevertheless several studies indicate
that despite these costs the clinical use of BMP-2 and BMP-
7 is still recommended from a health economic point of
view [49, 50]. Cost reductions for hospitals are mainly
related to shorter surgery time due to the absence of the
bone grafting procedure and faster discharge of the patient.
For the patients treated with rhBMP-2, the time to return to
work is significantly reduced, as is the risk of revision
surgery [49]. In a comparative study BMP-7 treatment was
found to be as efficient as autologous bone graft, but the
average cost was 6.78% higher, mainly due to the price of
BMP-7 [50]. A systematic review on the clinical and cost-
effectiveness of BMPs concluded that the use of BMPs was
associated with a reduced operating time, improvement in
clinical outcomes and a shorter hospital stay as compared to
the use of autograft [51]. The proportion of secondary
interventions tended to be lower in the BMP group than in
the controls, but this was not statistically significant. In
non-unions, there is no evidence that BMP treatment is
more or less effective than bone grafts; however, it is
currently used when bone grafts and other treatments have
failed. According to the results of economic evaluation, for
spinal fusion the use of BMP is unlikely to be cost-effective
[51]. As for any novel treatment, further studies, preferably
randomised, controlled blinded and with sufficient power
and proper controls, are needed to assess the clinical
effectiveness of the use of BMPs for bone union [52–54].
These studies are currently being performed, e.g. BMP-7
for tibial fractures in Ghent, Belgium (NCT00551941). The
issue of cost-effectiveness should be discussed afterwards.
One important issue, the expensive manufacturing of
BMPs, can be overcome by new and cheaper production
methods, such as the method described by von Einem et al.
for rhBMP-2 [55]. Another alternative could be the use of
inexpensive compounds that locally stimulate the induction
of BMPs. Statins have been shown to increase the
expression of BMP-2 [56]. Locally applied simvastatin
improved fracture healing in a rat model similar to the
effect of BMP-2 [57]. Statins are relatively cheap and well-
tested drugs and their BMP-stimulating properties may
contain new possibilities in terms of fracture healing. In this
respect, the recently discovered soluble form of the BMP
activity-enhancing co-receptor endoglin also deserves fu-
ture investigation [28].
Blocking antagonists
Because rhBMP treatment has some disadvantages, the
quest for alternative treatment is still ongoing. Blocking of
the function of BMP antagonists may provide such an
alternative. By inhibiting BMP antagonists an environment
can be created in which the rhBMP therapy will be more
International Orthopaedics (SICOT) (2011) 35:1271–1280 1275effective. The best effects will be reached by inhibition of
factors antagonising BMP activity at the level of the callus
[23]. To date, very little literature is available about the
manipulation of BMP antagonists to promote bone healing
in humans. The BMP inhibitor α2-HS-glycoprotein (Ahsg)
was found to control the osteogenic potency of ectopically
applied BMP [58]. The BMP antagonist noggin showed
potential clinical applications in a mouse model [25].
Noggin-suppressed osteoblasts are suggested as a method
of treatment to avoid the need for exogenous application of
BMPs [59]. The use of inhibiting monoclonal antibodies
againstsclerostin,anindirectBMPantagonist[60], has shown
increased bone formation in rodents and primates, suggesting
a therapeutic role in osteoporosis [24]. By manipulating the
balance with antagonists, endogenous BMP activity can be
up-regulated throughout the process of fracture healing,
avoiding issues of timing, dose and delivery. These prelimi-
nary findings suggest that antagonists may have a therapeutic
role in regulating the size or shape of BMP-containing
implants and in preventing heterotopic ossification.
Application of other BMP family members
Several studies investigating the potential of BMPs indi-
cated that other members of the BMP family, different than
the currently used BMP-2 and BMP-7, might provide
attractive alternatives for fracture treatment (Table 2). In
vitro, most human BMPs were able to stimulate osteogen-
esis in mature osteoblasts, but BMP-6 and BMP-9 were
more efficient in driving osteoblast differentiation of
mesenchymal stem cells than BMP-2 and BMP-7 [17].
BMP-6 and BMP-9 were also found to be more effective
osteogenic factors in a mouse model for bone regeneration
compared to BMP-2 and BMP-7 [61]. Moreover, BMP-6,
BMP-9 and BMP-4 showed more osteogenic potential than
the approved rhBMPs in a rat model [9]. Also in rat, an
adenoviral vector carrying BMP-6 (AdBMP-6) produced
more rapid tissue calcification and induced bone formation
by both intramembranous and endochondral ossification
compared to an adenoviral vector containing BMP-2
(AdBMP-2) or BMP-4 (AdBMP-4) [62]. Although these
model studies suggest an effect of BMP-4 and BMP-6 on
fracture healing, the osteogenic activity of these BMPs has
not yet adequately been investigated in humans (Table 1).
Recently, BMP-6 displayed significantly more pronounced
BMP reporter activation, osteoblast differentiation and
stimulation of fracture healing than the most closely related
family member BMP-7 [19, 63]. The higher ultimate effect
is not due to the stimulating potential of BMP-6, but due to
differences in the noggin-mediated negative feedback loop
induced by these BMPs. Upon siRNA-mediated knock-
down of noggin, BMP-7 appeared to be as effective in
inducing BMP reporter activation and osteoblast differen-
tiation as BMP-6. BMP-6 stimulation not only resulted in
lower induction of noggin expression compared to BMP-7,
but BMP-6 was also found to be almost insensitive to
noggin-mediated inhibition. A lysine at position 60 (Lys-
60) was identified as a key residue conferring noggin
resistance within the BMP-6 protein, and introducing a
lysine residue at the position corresponding to BMP-6 Lys-
60 in BMP-7 and BMP-2 made these mutants more
resistant to inhibition by noggin. Interestingly, BMP-9 also
contains a lysine residue at this position and is, like BMP-6,
not inhibited by noggin [18, 19]. BMP-9 also emerged as
one of the most potent inducers of osteogenic differentia-
tion [9, 17, 36, 61, 64, 65]. BMP-9 was shown to promote
chondrogenic lineage differentiation of human multipotent
mesenchymal cells. BMP-9 was more potent to maintain
the expression of chondrocyte-specific extracellular matrix
molecules than BMP-2 [66]. Combined injection in mice of
BMP-9 and BMP-3, a known inhibitor of BMPs, resulted in
the formation of bone, indicating that BMP-3 did not have
the inhibiting effect which it has on other BMPs [61]. The
highly increased osteogenic activity observed with BMP-9
may be due to the fact that it is not affected by BMP
Table 2 Properties of several BMPs. The resistance to noggin is
caused by a lysine residue at position 60 in the molecule. Also the
ability to induce differentiation in pluripotent and preosteoblastic cells
is described. The possible induction of mineralised matrix by the
different BMPs is described. The potency of superior BMPs with
reference to less potent BMPs is explained
BMP-2 BMP-6 BMP-7 BMP-9
Resistance to noggin No [18, 19] Yes [19]N o [ 19] Yes [18, 19]
Inducing differentiation in
stem cells [17]
Notable increase
in induction
Notable increase
in induction
Detectable, but marginal
induction
Notable increase in induction
Inducing differentiation in
preosteoblastic cells [17]
Marked increase
in induction
Marked increase
in induction
Increase of induction at
later time point
Marked increase in induction
Induction of mineralised
matrix [17]
Readily
detectable nodules
Readily detectable
nodules
Sparse, but detectable
nodules
Readily detectable nodules
Specific BMP more potent
than other BMPs
More potent than
BMP-2 [62]
Higher induction of expression with
specific molecules than BMP-2 [66]
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ing the negative feedback loop. Alternatively, it is possible
to engineer BMP variants, such as variants of the currently
used BMP-2 and BMP-7, with increased noggin resistance
by substituting the amino acid residue corresponding to
BMP-6 Lys-60 for a lysine residue. An alternative for the
current treatment with BMP-2 or BMP-7 homodimers, the
use of BMP-2/7 heterodimers could also be considered.
These heterodimers display increased osteogenic potential
and improved fusion compared with BMP homodimers
[67]. Interestingly, BMP-2/7 heterodimers were found to
induce lower levels of noggin expression and to be almost
insensitive to noggin inhibition [68]. Recently, heterodimers
of BMP-2/6 have been shown to bind more strongly to
BMP receptors and are more osteogenic than BMP-2 [69].
Finally, another approach to enhance BMP-induced bone
formation might be a combination with TGF-β. TGF-β is
generally considered to inhibit BMP signalling [70, 71].
However, recently we demonstrated that the inhibitory
effects of TGF-β on BMP-induced osteoblast differentia-
tion depend on the timing and environmental conditions of
the co-stimulation, and that under well-controlled condi-
tions, transient co-application of TGF-β can actually
promote BMP-induced differentiation towards the osteo-
blast lineage [72]. Co-application of TGF-β1 with BMP-2
has been shown to accelerate bone formation, to increase
total bone volume and to improve fracture healing in mice
compared to application of BMP-2 alone [73]. Since TGF-
β seems to stimulate early BMP-induced osteoblast
differentiation whereas it inhibits late osteoblast differenti-
ation and mineralisation, it can be considered to initially
combine BMP and TGF-β treatment followed by applica-
tion of TGF-β antagonists to enhance the bone fracture
healing process.
Conclusion
The efficacy of the use of BMPs to enhance fracture healing
is still controversial. The BMPs currently used to enhance
bone fracture healing, rhBMP-2 and rhBMP-7, are expen-
sive and have side effects. Other BMPs, such as BMP-6 and
BMP-9, were shown to be more potent in vivo and might
turn out to be more effective for the treatment of delayed
and non-union fractures. As a consequence of the resistance
of BMP-6 and BMP-9 to noggin-mediated inhibition,
lower, more physiological amounts of these BMPs will be
needed to improve fracture healing. Optimisation of the
BMP products used and cheaper production methods will
inevitably stimulate the clinical use of BMPs for bone
fracture healing. A lot of questions still have to be solved to
establish when and where the use of BMPs is the most
profitable and effective.
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